Dexanabinol

Summary

Dexanabinol (CHEMBL334533) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including brain injury and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 4
• Chemistry: 386.6 Da · C25H38O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL334533
Name	Dexanabinol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	107778
Molecular formula	C25H38O3
Molecular weight	386.6
InChIKey	SSQJFGMEZBFMNV-PMACEKPBSA-N

SMILES: CCCCCCC(C)(C)C1=CC(=C2[C@H]3CC(=CC[C@@H]3C(OC2=C1)(C)C)CO)O

IUPAC name: (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol

Also known as: (+)-HU-210, Dexanabinol, HU-211, PA-50211, PRS-211007, Sinnabidol, DEXANABINOL

Patent coverage: 479 distinct patent families (1,014 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 956 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Cannabinoid receptor 1, Cannabinoid receptor 2, Cannabinoid receptor 1.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 7 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CNR2	9.6	EC50	0.25	nM	CHEMBL_ACT_1844613
CNR1	9.22	EC50	0.6	nM	CHEMBL_ACT_1847031
CNR1	7.73	Ki	18.6	nM	CHEMBL_ACT_1501052
CNR1	7.72	Ki	19	nM	CHEMBL_ACT_1847008
CNR2	6.82	Ki	150	nM	CHEMBL_ACT_1846061
P20272	6.44	Ki	360	nM	CHEMBL_ACT_276151
P20272	5.7	Ki	1990	nM	CHEMBL_ACT_14574121

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
brain injury	3	MONDO:0043510	MONDO:0043510
neoplasm	1	MONDO:0005070	EFO:0000616
brain cancer	1	MONDO:0001657	MONDO:0001657

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE1	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00129857	PHASE3	COMPLETED	Dexanabinol in Severe Traumatic Brain Injury
NCT01489826	PHASE1	COMPLETED	A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours
NCT01654497	PHASE1	COMPLETED	Dexanabinol in Patients With Brain Cancer
NCT02423239	PHASE1	UNKNOWN	A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).